J
J.M. Kerst
Researcher at Netherlands Cancer Institute
Publications - 26
Citations - 1560
J.M. Kerst is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Cancer & Bladder cancer. The author has an hindex of 15, co-authored 26 publications receiving 1300 citations. Previous affiliations of J.M. Kerst include University Medical Center Utrecht & University of Adelaide.
Papers
More filters
Journal ArticleDOI
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
Nathan I. Cherny,Richard Sullivan,Urania Dafni,J.M. Kerst,A. Sobrero,Christoph C. Zielinski,E.G.E. de Vries,Martine Piccart,Martine Piccart +8 more
TL;DR: The ESMO-MCBS is an important first step to the critical public policy issue of value in cancer care, helping to frame the appropriate use of limited public and personal resources to deliver cost-effective and affordable cancer care.
Journal ArticleDOI
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience
Piotr Rutkowski,Alessandro Gronchi,Peter Hohenberger,Sylvie Bonvalot,Patrick Schöffski,Sebastian Bauer,Elena Fumagalli,Paweł Nyckowski,Buu Phuc Nguyen,J.M. Kerst,Marco Fiore,Elżbieta Bylina,Mathias Hoiczyk,Annemieke Cats,Paolo G. Casali,Axel Le Cesne,Jürgen Treckmann,Eberhard Stoeckle,Johannes H. W. de Wilt,Stefan Sleijfer,R. Tielen,Winette T. A. van der Graaf,Cornelis Verhoef,Frits van Coevorden +23 more
TL;DR: The authors' analysis comprising the largest group of GIST patients treated with neoadjuvant imatinib in routine practice indicates excellent long-term results of combined therapy in locally advanced GISTs.
Journal ArticleDOI
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.
Paolo G. Casali,John Zalcberg,Axel Le Cesne,Peter Reichardt,Jean-Yves Blay,Lars H. Lindner,Ian Judson,Patrick Schöffski,Serge Leyvraz,Antoine Italiano,Viktor Grünwald,Antonio López Pousa,Dusan Kotasek,Stefan Sleijfer,J.M. Kerst,Piotr Rutkowski,Elena Fumagalli,Pancras C.W. Hogendoorn,S. Litiere,Sandrine Marreaud,Winette T. A. van der Graaf,Alessandro Gronchi,Jaap Verweij +22 more
TL;DR: This trial was carried out on a worldwide intergroup basis, at the beginning of the learning curve of the use of imatinib, in a large population of patients with advanced GIST, likely pointing to a lower burden of disease.
Journal ArticleDOI
A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)
Christine Theodore,I. Skoneczna,István Bodrogi,M. G. Leahy,J.M. Kerst,Laurence Collette,K. Ven,Sandrine Marreaud,R.D.T. Oliver +8 more
TL;DR: The study fails to demonstrate a response rate significantly >30% and the observation regarding M0 patients suggests to repeat this study in the neo-adjuvant setting.
Journal ArticleDOI
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072
Bernd Kasper,Stefan Sleijfer,Saskia Litière,Sandrine Marreaud,Jaap Verweij,Rachel Hodge,Sebastian Bauer,J.M. Kerst,W.T.A. van der Graaf +8 more
TL;DR: A retrospective analysis on pooled data from two EORTC trials on pazopanib in STS confirmed the importance of known prognostic factors in metastatic STS patients treated with systemic treatment, such as performance status and tumor grading, and additionally hemoglobin at baseline as new prognostic factor.